Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
98.85 EUR | -1.15% | -2.51% | -1.74% |
Apr. 26 | BioMérieux: share price rises, analyst remains Buy | CF |
Apr. 26 | BIOMÉRIEUX : Berenberg raises its target | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
Weaknesses
- The firm trades with high earnings multiples: 25.73 times its 2024 earnings per share.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.74% | 12.62B | B+ | ||
-9.59% | 7.67B | B- | ||
-1.20% | 5.41B | B | ||
+26.10% | 4.62B | C | ||
+0.02% | 4.57B | C | ||
-53.02% | 3.22B | D+ | ||
+6.42% | 2.59B | - | - | |
-14.95% | 2.05B | B- | ||
-8.29% | 1.79B | D+ | ||
+0.42% | 1.76B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIM Stock
- Ratings bioMérieux